Biogen Inc

BIIB is in a Stage 2 advancing regime with a clear sequence of higher highs and higher lows underpinned by rising EMAs. Medium-term directional bias remains bullish, but price is currently extended and overbought relative to the short-term EMAs. Short-term execution readiness is neutral; we will stalk a pullback into the 9 and 21 EMA area for higher-probability participation.

• ↑Q1 2026 revenue $2.5B (+2% YoY) and GAAP diluted EPS $2.15 (+31% YoY)
• ↑Growth products (Lekembi, Zerzuve) delivered $851M revenue with 80% treatment persistence at 18 months
• ↓MS portfolio revenue declined 11% YoY due to generic competition, notably in Europe